• Home
  • Temozolomide 250mg
  • Temozolomide 250mg

Temozolomide 250mg

52090

Temozolomide is used with radiotherapy and then on its own for newly diagnosed glioblastoma, an aggressive brain cancer.

It is also used for anaplastic astrocytoma or other glioma settings when the tumour has come back or worsened after earlier treatment.

Usual adult dose range: 75mg/m2 once daily during radiotherapy, then 150mg/m2 to 200mg/m2 once daily for 5 days of each 28-day cycle in many maintenance or recurrent brain tumour regimens.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.